Singh Jitender, Peters Nitin J, Avti Pramod, Trehan Amita, Mahajan J K, Menon Prema, Bansal Deepak, Kanojia Ravi Prakash
Department of Pediatric Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Department of Pediatric Surgery, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
J Pediatr Surg. 2025 Feb;60(2):161887. doi: 10.1016/j.jpedsurg.2024.161887. Epub 2024 Aug 30.
Neuroblastoma (NBL), is the most common, non-CNS solid tumor of childhood. This disease presents with unique biological and clinical challenges necessitating accurate diagnosis, prognosis assessment, treatment, and vigilant monitoring. Liquid biopsy is an upcoming, innovative, and non-invasive diagnostic modality. It has the potential to detect tumors and perform therapeutic monitoring through the analysis of circulating biomarkers in blood, urine, saliva, and other bodily fluids.
This scoping review offers an in-depth exploration, of the current landscape of liquid biopsy-based biomarkers in NBL. The review looks at the clinical implications, prevalent challenges, and future outlook of their clinical applications in NBL. The scoping review adhered to the guidelines of the PRISMA extension for scoping reviews, known as PRISMA-ScR, as the skeletal framework. The review involved comprehensive searches for liquid biopsy-based biomarkers in NBL across multiple databases, including PUBMED, EMBASE, SCOPUS, and WEB of Science, without restrictions.
The scoping review process uncovered a significant body of literature (n = 201) that underwent meticulous scrutiny, ultimately leading to the final selection of studies (n = 15). The liquid biopsy biomarkers included circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosomes, and other entities in bodily fluids. Their evaluation focused on associations with clinical outcomes such as overall survival, event-free survival, and risk stratification in NBL.
Our findings highlight the potential of liquid biopsy biomarkers to revolutionize NBL diagnosis and therapeutic monitoring. This rapidly evolving frontier in pediatric oncology suggests significant advancements in precision medicine for the management of NBL.
神经母细胞瘤（NBL）是儿童期最常见的非中枢神经系统实体瘤。这种疾病呈现出独特的生物学和临床挑战，需要准确的诊断、预后评估、治疗和密切监测。液体活检是一种新兴的、创新的非侵入性诊断方式。它有潜力通过分析血液、尿液、唾液和其他体液中的循环生物标志物来检测肿瘤并进行治疗监测。
本综述对基于液体活检的生物标志物在NBL中的当前情况进行了深入探索。该综述探讨了其在NBL中的临床意义、普遍存在的挑战以及临床应用的未来前景。本综述以PRISMA扩展版（即PRISMA-ScR）的指南为框架进行范围界定。该综述在多个数据库（包括PUBMED、EMBASE、SCOPUS和科学网）中对基于液体活检的NBL生物标志物进行了全面检索，无任何限制。
综述过程发现了大量文献（n = 201），经过仔细筛选，最终选定了15项研究。液体活检生物标志物包括循环肿瘤细胞（CTC）、循环肿瘤DNA（ctDNA）、外泌体和体液中的其他物质。它们的评估重点是与NBL的总生存期、无事件生存期和风险分层等临床结果的关联。
我们的研究结果突出了液体活检生物标志物在革新NBL诊断和治疗监测方面的潜力。儿科肿瘤学这一快速发展的前沿领域表明，在NBL治疗的精准医学方面将取得重大进展。
